Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Abbott Laboratories (NYSE:ABT) discovers, develops, manufactures, and sells healthcare products worldwide. If You Bought Abbott Laboratories Stock 10 Years Ago The company's stock traded at approximately $49.14 per share 10 years ago. If you had invested $10,000, you could have bought roughly 204 shares. Currently, shares trade at $134.92, meaning your investment's value could have grown to $27,456 from stock price appreciation alone. However, Abbott Laboratories also paid dividends during these 10 years. Don't Miss: Hasbro, MGM, and Skechers trust this AI marketing firm — Invest at $0.60/share before it's too late. Deloitte's fastest-growing software company partners with Amazon, Walmart & Target – Last Chance to get 4,000 of its pre-IPO shares for just $0.30/share! Abbott Laboratories' dividend yield is currently 1.74%. Over the last 10 years, it has paid about $16 in dividends per share, which means you could have made $3,256 from dividends alone. Summing up $27,456 and $3,256, we end up with the final value of your investment, which is $30,712. This is how much you could have made if you had invested $10,000 in Abbott Laboratories stock 10 years ago. This means a total return of 207.12%. However, this figure is less than the S&P 500 total return for the same period, which was 234.20%. Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — you can become an investor for $0.80 per share today. What Could The Next 10 Years Bring? Abbott Laboratories has a consensus rating of "Buy" and a price target of $137.12 based on the ratings of 27 analysts. The price target implies a nearly 2% potential upside from the current stock price. On April 16, the company announced its Q1 2025 earnings, posting revenues of $10.36 billion, compared to the consensus of $10.40 billion, as reported by Benzinga. The U.S. MedTech giant reported adjusted EPS of $1.09, beating the consensus of $1.07. "Once again, Abbott's diversified business model delivered top-tier sales and EPS growth," said CEO Robert Ford. "It is this diversification and execution that allows Abbott to navigate through periods of uncertainty and continually deliver sustainable growth." See Also: Nancy Pelosi Invested $5 Million In An AI Company Last Year — Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000. Abbott reaffirmed its full-year 2025 adjusted EPS guidance in the range of $5.05 to $5.25, compared to the consensus estimate of $5.15. Q2 2025 adjusted EPS is expected to be between $1.23 and $1.27, compared to the consensus of $1.25. Story Continues Given the expected downside potential, growth-focused investors may not find Abbott Laboratories stock attractive. Conversely, the stock can be a good option for income-focused investors, who can benefit from the company's solid dividend yield of 1.74% and consistent hikes. Abbott Laboratories has raised its dividend consecutively for the last 51 years. Check out this article by Benzinga for three more stocks offering high dividend yields. Read Next: Invest Where It Hurts — And Help Millions Heal: Invest in Cytonics and help disrupt a $390B Big Pharma stronghold. ‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. You can invest today for just $0.30/share with a $1000 minimum. Image: Shutterstock Send To MSN: 0 This article If You Invested $10K In Abbott Laboratories Stock 10 Years Ago, How Much Would You Have Now? originally appeared on Benzinga.com View Comments
If You Invested $10K In Abbott Laboratories Stock 10 Years Ago, How Much Would You Have Now?
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...